First Manhattan’s Cabaletta Bio CABA Stock Holding History

First Manhattan’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,600	Closed	-$44.4K	–	757
2024 Q1	$44.4K	Hold	2,600	–	–	﹤0.01%	915
2023 Q4	$59K	Sell	2,600 -115,000	-98%	-$1.93M	﹤0.01%	833
2023 Q3	$1.79M	Hold	117,600	–	–	0.01%	319
2023 Q2	$1.52M	Buy	+117,600	New	+$1.28M	0.01%	341
2022 Q4	–	Sell	-500	Closed	–	–	1701
2022 Q3	$0	Hold	500	–	–	﹤0.01%	1525
2022 Q2	$0	Hold	500	–	–	﹤0.01%	1549
2022 Q1	$1K	Hold	500	–	–	﹤0.01%	1521
2021 Q4	$1K	Hold	500	–	–	﹤0.01%	1516
2021 Q3	$6K	Hold	500	–	–	﹤0.01%	1350
2021 Q2	$4K	Hold	500	–	–	﹤0.01%	1420
2021 Q1	$5K	Hold	500	–	–	﹤0.01%	1330
2020 Q4	$6K	Hold	500	–	–	﹤0.01%	1188
2020 Q3	$5K	Hold	500	–	–	﹤0.01%	1192
2020 Q2	$5K	Buy	+500	New	+$3.83K	﹤0.01%	1237

Other funds holding CABA

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

First Manhattan's CABA Position: Q2 2024 in Review

First Manhattan sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 2,600 shares — an estimated $44.4K sold.

First Manhattan first reported a position in CABA in Q2 2020 and held it in 14 quarters. The position peaked at $1.79M in Q3 2023. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

First Manhattan reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 2,600 Cabaletta Bio shares in Q2 2024, an estimated $44.4K.
First Manhattan first reported a position in Cabaletta Bio in Q2 2020 and held it in 14 quarters.
First Manhattan's Cabaletta Bio position peaked at $1.79M in Q3 2023.
142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.